Loading…
Employees: 38
Size Onconic Therapeutics (476060.KS) is a South Korea Health Care company (Biotechnology) with a market value of $391M, the 399th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩11,680 on 6 Nov 2026.
Performance Over six months the shares fell 45.0%, against -29.2% for the median peer and -24.5% for the South Korea market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 179.3% over the last twelve months (peer median +2.6%); the operating margin is 21.1% (peer median -143.7%).
Valuation It trades at 5.7× enterprise value to sales against a peer median of 5.3× (7th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +725%, so the hurdle is -723 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 48.7 points above its cost of capital (5.6% WACC).
Next results Next results expected around 17 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩82.2B | ₩53.4B | ₩14.8B | ₩21.1B | ₩95.0M |
| Revenue growth | — | +260% | -30% | +22,064% | — |
| Gross profit | ₩37.2B | ₩25.5B | ₩8.53B | ₩19.3B | n/a |
| EBITDA | ₩17.9B | ₩13.1B | -₩4.35B | ₩2.69B | -₩14.6B |
| Net income | ₩24.3B | ₩15.8B | -₩8.09B | ₩1.68B | -₩14.4B |
| Free cash flow | ₩16.5B | ₩11.1B | -₩7.98B | ₩2.98B | -₩17.5B |
| Capital expenditure | ₩317M | ₩303M | ₩141M | ₩1.16B | ₩2.58B |
| Total debt | ₩271M | ₩126M | ₩308M | ₩14.1B | ₩12.1B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 476060.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.7% | -10.8% | 6th lowest of 21 |
| 6-month return | -45.0% | -29.2% | 4th lowest of 21 |
| Distance from 52-week high | -59.6% | -47.4% | 5th lowest of 21 |
| Revenue growth (TTM) | +179.3% | +2.6% | 5th highest of 17 |
| Operating margin | 21.1% | -143.7% | 4th highest of 17 |
| EV / Sales | 5.7× | 5.3× | 7th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 2.0% | -5.9% | 3rd least demanding of 5 |
| Growth delivered (Del g) | +725.2% | +8.9% | highest of 4 |
| Hurdle (Req g minus delivered) | -723.3 pp | -2.4 pp | least demanding of 4 |
| ROIC minus cost of capital | +48.7 pp | -9.1 pp | 2nd highest of 12 |
| EV / EBITDA | 26.2× | 6.0× | most expensive of 5 |
| Net debt / EBITDA | -3.5× | -1.3× | 3rd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | 28.4× | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | 5.4× | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | 2.7× | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | 5.3× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | 3,686.9× | n/a | n/a |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | 0.9× | -15.8% | +197.3% |
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | 2.4× | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 1.6× | 43.0% | +8.9% |
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | 775.0× | n/a | n/a |
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | 0.7× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 2.5× | -20.2% | n/a |
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 1.8× | 4.1% | +6.5% |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | 23.3× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | 7,653.4× | n/a | n/a |
| Arvinas ARVN | United States | $420M | -37% | -12% | -10% | n/a | n/a | n/a |